All Stories

Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion.

Jun 12, 2025 - 17:40
 0
Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi
Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion.
Read More

Tags:

Previous Article

AstraZeneca takes $181M hit in Syntimmune shareholder lawsuit on top of previous...

Next Article

Medtronic adopts familiar name for its planned diabetes spinout: MiniMed

Related Posts

FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer

FDA limits Merck's Keytruda, Bristol Myers' Opdivo in s...

Jun 9, 2025  0

A Fierce breakdown of the 'most favored nation' executive order

A Fierce breakdown of the 'most favored nation' executi...

May 16, 2025  0

Riding its Peloton buyout, Merck rolls to third FDA nod for potential blockbuster Welireg

Riding its Peloton buyout, Merck rolls to third FDA nod...

May 15, 2025  0